Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.

Akdag C., SAHIN S., BUTTINI F., BALDUCCI A., MONTANARI S., VURAL I., ...Daha Fazla

Drug development and industrial pharmacy, cilt.43, ss.1378-1389, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/03639045.2017.1318902
  • Dergi Adı: Drug development and industrial pharmacy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1378-1389
  • Anahtar Kelimeler: Dry powder inhaler, ciprofloxacin, levofloxacin, mucolytic, permeability, cystic fibrosis, PULMONARY DRUG-DELIVERY, CELL-LINE, CALU-3, LUNG, PHARMACOKINETICS, MICROSPHERES, TOLERABILITY, OPTIMIZATION, MOXIFLOXACIN, DEHYDRATION
  • Hacettepe Üniversitesi Adresli: Evet